PlainPharmaWatch

CMS Open Payments · Tool

Datascope Corp. vs Rigel Pharmaceuticals, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Datascope Corp. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 3,460, versus 175 for the other company. Its single largest recorded recipient represents 50.4% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Datascope Corp.
HHI 3,460 · top recipient 50.4%
Ranked #511 of 1,838 companies by HHI
Rigel Pharmaceuticals, Inc.
HHI 175 · top recipient 5.4%
Ranked #1,586 of 1,838 companies by HHI

Payment Overview

Company A

Datascope Corp.

Total Payments
$1.6M
% of Industry
0.0%
Transactions
14
Avg per Transaction
$114.2K
Recipients
14
Avg per Recipient
$114.2K
Payment Types
2
Top Payment Type
Acquisitions
Total Payments
$1.6M
% of Industry
0.0%
Transactions
5,863
Avg per Transaction
$273.50
Recipients
5,780
Avg per Recipient
$277.43
Payment Types
7
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Datascope Corp. vs Rigel Pharmaceuticals, Inc. - total reported payments in CMS Open Payments PY2024

Rigel Pharmaceuticals, Inc.$1.6MDatascope Corp.$1.6M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Datascope Corp.

Acquisitions $1.6M

100.0%

Food and Beverage $255.49

0.0%

Rigel Pharmaceuticals, Inc.

Compensation for Services Other Than Consulting $406.4K

39.1%

Honoraria $206.5K

19.9%

Food and Beverage $147.9K

14.2%

Consulting Fee $99.6K

9.6%

Travel and Lodging $89.4K

8.6%

Education $68.7K

6.6%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Datascope Corp.

  1. 1

    Cleveland Clinic Hospital

    $805,384.00 · 2 txns

  2. 2

    HARISH LECAMWASAM

    $436,448.00 · 2 txns

  3. 3

    PETER PRONOVOST

    $151,576.00 · 2 txns

  4. 4

    THOMAS MARK

    $131,208.00 · 2 txns

  5. 5

    MICHAEL SMITH

    $74,368.00 · 2 txns

Rigel Pharmaceuticals, Inc.

  1. 1

    JOSEPH BAILES

    $56,000.00 · 5 txns

  2. 2

    GEORGE YAGHMOUR

    $41,560.85 · 23 txns

  3. 3

    THOMAS LEBLANC

    $36,464.79 · 16 txns

  4. 4

    SURESH RATNAM

    $35,109.42 · 20 txns

  5. 5

    PRANEETH BARATAM

    $35,016.51 · 21 txns

Summary Comparison

Metric Datascope Corp. Rigel Pharmaceuticals, Inc.
Total Payments $1.6M $1.6M
% of Industry Total 0.0% 0.0%
Transaction Count 14 5,863
Avg per Transaction $114.2K $273.50
Recipient Count 14 5,780
Avg per Recipient $114.2K $277.43
Payment Type Count 2 7
Top Payment Type Acquisitions Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.